Accrued Liabilities - Maat Pharma SA (PAR:MAAT) - Alpha Spread
M

Maat Pharma SA
PAR:MAAT

Watchlist Manager
Maat Pharma SA
PAR:MAAT
Watchlist
Price: 7.3 EUR 2.24% Market Closed
Market Cap: 101.4m EUR
Have any thoughts about
Maat Pharma SA?
Write Note

Maat Pharma SA
Accrued Liabilities

Last Value
3-Years 3-Y CAGR
5-Years 5-Y CAGR
10-Years 10-Y CAGR
Quarterly
Annual
|

Maat Pharma SA
Accrued Liabilities Peer Comparison

Comparables:
VLA
NANO
IPH
GNFT
ALERS

Competitive Accrued Liabilities Analysis
Latest Figures & CAGR of Competitors

Company Accrued Liabilities CAGR 3Y CAGR 5Y CAGR 10Y
M
Maat Pharma SA
PAR:MAAT
Accrued Liabilities
€1.3m
CAGR 3-Years
37%
CAGR 5-Years
42%
CAGR 10-Years
N/A
Valneva SE
PAR:VLA
Accrued Liabilities
€41.5m
CAGR 3-Years
50%
CAGR 5-Years
36%
CAGR 10-Years
26%
Nanobiotix SA
PAR:NANO
Accrued Liabilities
€7.4m
CAGR 3-Years
4%
CAGR 5-Years
110%
CAGR 10-Years
23%
Innate Pharma SA
PAR:IPH
Accrued Liabilities
N/A
CAGR 3-Years
N/A
CAGR 5-Years
N/A
CAGR 10-Years
N/A
Genfit SA
NASDAQ:GNFT
Accrued Liabilities
€4.2m
CAGR 3-Years
-2%
CAGR 5-Years
7%
CAGR 10-Years
N/A
Eurobio Scientific SA
PAR:ALERS
Accrued Liabilities
€6.1m
CAGR 3-Years
5%
CAGR 5-Years
20%
CAGR 10-Years
6%

See Also

What is Maat Pharma SA's Accrued Liabilities?
Accrued Liabilities
1.3m EUR

Based on the financial report for Dec 31, 2023, Maat Pharma SA's Accrued Liabilities amounts to 1.3m EUR.

What is Maat Pharma SA's Accrued Liabilities growth rate?
Accrued Liabilities CAGR 5Y
42%

Over the last year, the Accrued Liabilities growth was 5%. The average annual Accrued Liabilities growth rates for Maat Pharma SA have been 37% over the past three years , 42% over the past five years .

Back to Top